[4-[2-[3-Ethynyl-5-[2-(2-methoxyethoxy)ethylcarbamoyl]anilino]pyrimidin-4-yl]oxynaphthalen-1-yl]carbamic acid

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: [4-[2-[3-Ethynyl-5-[2-(2-methoxyethoxy)ethylcarbamoyl]anilino]pyrimidin-4-yl]oxynaphthalen-1-yl]carbamic acid
• 英文别名: [4-[2-[3-ethynyl-5-[2-(2-methoxyethoxy)ethylcarbamoyl]anilino]pyrimidin-4-yl]oxynaphthalen-1-yl]carbamic acid
• 化学式: C₂₉H₂₇N₅O₆
• 分子量: 541.6
• InChiKey: MHOHMLYXNXTEGC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  40
• 可旋转键数：
  13
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  144
• 氢给体数：
  4
• 氢受体数：
  9

文献信息

• Kinase inhibitors
  申请人：Topivert Pharma Limited

  公开号：US10301288B2

  公开（公告）日：2019-05-28

  There are provided compounds of formula (III), or a salt or protected derivative thereof, wherein Z2 represents a structural fragment of formula (V), wherein R1, Ra, Rb, X and Y have meanings given in the description, which compounds have antiinflammatory activity, for example through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.

  提供了式(III)化合物、 或其盐或受保护的衍生物，其中 Z2 代表式（V）的结构片段、 其中 R1、Ra、Rb、X 和 Y 具有描述中给出的含义，这些化合物具有抗炎活性，例如通过抑制以下成员中的一个或多个：p38 丝裂原活化蛋白激酶家族；Syk 激酶；以及酪氨酸激酶 Src 家族成员），可用于治疗，包括药物组合，尤其是用于治疗炎症性疾病，包括肺、眼和肠道的炎症性疾病。
• KINASE INHIBITORS
  申请人：Respivert Limited

  公开号：EP2970190A1

  公开（公告）日：2016-01-20
• US9850233B2
  申请人：——

  公开号：US9850233B2

  公开（公告）日：2017-12-26
• [EN] KINASE INHIBITORS<br/>[FR] INHIBITEURS DE KINASES
  申请人：RESPIVERT LTD

  公开号：WO2014140582A1

  公开（公告）日：2014-09-18

  There are provided compounds of formula (I), wherein: Y represents NR2R3; one of R2 and R3 represents -[C2-4 alkylene-O]1-12-[C2-4 alkylene]-R2a and the other of R2 and R3 has a meaning given in the description; and R, R1, R2a, Ra, Rb, Q, X and Y have meanings given in the description, which compounds have antiinflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.